Home General Physiology and Biophysics 2026 General Physiology and Biophysics Vol.45, No.1, p, 77–91, 2026

Journal info


Founded: 1982
ISSN 1338-4325 (online)
ISSN 0231-5882 (print)
Published in English,
6 times per year

Aims and Scope
Editorial Info
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

General Physiology and Biophysics Vol.45, No.1, p, 77–91, 2026

Title: Platelet-rich miR-21 is a predictive biomarker in osteosarcoma and promotes osteosarcoma cell malignancy
Author: Xi’an Pan, Shishi Dong, Farui Sun, Yuanjin Zhang, Guofu Zhang, Jun Li, Bingxia Liu
Abstract: Platelet-derived microRNAs (miRNAs) are regarded as diagnostic biomarkers as well as potent regulators of cancer development. The expression of miR-21, a vital miRNA, is elevated in the tumor tissues of osteosarcoma (OS) patients. However, platelet-derived miR-21 in OS is unknown. Here, we found that the level of miR-21 is increased in the serum of OS patients. The miR-21 level is associated with advanced tumor stages and poorer clinical outcomes in OS patients. Moreover, platelet-derived microvesicles (PMVs) from OS patients (OS-PMVs) significantly enhanced the miR-21 profile in MG63 OS cells. Functional assays revealed that the proliferation and migration of MG63 cells were promoted by OS-PMV incubation or the transfection of miR-21 mimics, whereas the sensitivity of MG63 cells to methotrexate (MTX), doxorubicin (ADM), and cisplatin (DDP) was reduced. However, inhibiting miR-21 partially reversed the OS-PMV-mediated effects. Furthermore, programmed cell death 4 (PDCD4) was identified as a potential target of miR-21 in OS. miR-21 considerably inhibited PDCD4 expression in MG63 cells and reversed the antitumor effects mediated by PDCD4 overexpression. In conclusion, our results suggest that platelet-rich miR-21 may promote the development of OS by targeting PDCD4.
Keywords: Osteosarcoma — miR-21 — Platelets — Malignancy — Biomarker
Year: 2026, Volume: 45, Issue: 1 Page From: 77, Page To: 91
doi:10.4149/gpb_20250371
Price: Call for Pricing





© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.